FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
INOPLYMOUTH MEETING, Pa., Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and...
INOVIO Reports Inducement Grant Under Inducement Plan
INOPLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an...
INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults
INOComplete submission of the Biologics License Application (BLA) remains on track for 2H25 with the goal of file acceptance by U.S. Food and Drug Administration (FDA) by end of 2025 PLYMOUTH MEETING, Pa., Aug. 26, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on...
INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
INOPLYMOUTH MEETING, Pa., Aug. 25, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that a pre-recorded...
INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights
INOOn track to submit Biologics License Application (BLA) for INO-3107 in 2H25, with the goal of file acceptance by year end Completed design verification (DV) testing of CELLECTRA® 5PSP device required for BLA submission and requested rolling submission from US Food and Drug Administration...
Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP)
INORetrospective trial showed Overall Response Rate (ORR) improved to 86% at the end of the second 12-month period (Year 2) compared to 72% observed at the end of the initial 12-month Phase 1/2 trial (Year 1); the Complete Response (CR) rate improved to 50% for Year 2 from 28% for Year 1...
RBC Capital Reiterates Sector Perform on Inovio Pharmaceuticals, Maintains $5 Price Target
INOOppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13
INOInovio Pharmaceuticals Q1 EPS $(0.51) Up From $(1.31) YoY, Sales $65.34K Up from 0 YoY
INORBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $5
INOHC Wainwright & Co. Reiterates Neutral on Inovio Pharmaceuticals, Maintains $3 Price Target
INOInovio Pharmaceuticals Q4 2024 GAAP EPS $(0.65) Beats $(0.90) Estimate, Sales $117.000K Beat $30.000K Estimate
INOCitizens Capital Markets Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target
INOReported Earlier, INOVIO Announces 72-Week Data From COVID-19 DNA Antibody Trial With No Serious Adverse Events Or Immune Reactions
INOINOVIO Announces Phase 1/2 Trial Results Of INO-3107 For Recurrent Respiratory Papillomatosis With 81% Of Patients Requiring Fewer Surgeries; Plans BLA Submission In Mid-2025 For FDA Accelerated Approval, Aiming To Achieve First US DNA Medicine Approval
INOHC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $3
INOJMP Securities Reiterates Market Outperform on Inovio Pharmaceuticals, Maintains $18 Price Target
INOThe Analyst Landscape: 4 Takes On Inovio Pharmaceuticals
INOHC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $5
INOOppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $15
INORBC Capital Maintains Sector Perform on Inovio Pharmaceuticals, Lowers Price Target to $6
INOInovio Pharmaceuticals Q3 2024 GAAP EPS $(0.89) Beats $(1.15) Estimate
INO